



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area  
Dehradun, Uttarakhand 248 110, India  
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,  
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India  
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

January 10, 2025

To  
Listing / Compliance Department  
BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai – 400 001

To  
Listing / Compliance Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

**BSE CODE: 543329**

**NSE SYMBOL: WINDLAS**

Dear Sir/ Madam.

**Sub: Press Release**

Please find attached herewith press release on “Windlas Biotech’s new state-of-the-art Injectable facility receives GMP Certification”.

Kindly take the same on record.

Thanking you,

Yours faithfully,

**For Windlas Biotech Limited**

Ananta Narayan Panda  
**Company Secretary & Compliance Officer**

**Encl:** as above

## Press Release

### **Windlas Biotech's new state-of-the-art Injectable facility receives GMP Certification**

**Friday, 10<sup>th</sup> January 2025, Gurugram:** Windlas Biotech Limited, one of the leading domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India, is pleased to announce that it has received Good Manufacturing Practices (GMP) certification for its new State-of-the-Art Injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following the inspection in December 2024. The certification states, that the firm is following the **Good Manufacturing Practices as per World Health Organization (WHO) TRS Guidelines**.

**Commenting on this development, Mr. Hitesh Windlass, Managing Director, Windlas Biotech** said, *“The certification marks a new chapter in Windlas Biotech’s growth trajectory, bolstering its reputation as a trusted name in the pharmaceutical manufacturing sector. This underscores our unwavering commitment to quality, innovation, and compliance with the highest regulatory standards. The GMP certification for the injectable facility not only validates our adherence to stringent manufacturing protocols but also strengthens our ability to meet the growing demand for high-quality injectable pharmaceutical products, both domestically and globally.*

*The state-of-the-art facility has been designed with cutting-edge technology and advanced infrastructure to ensure the efficient and safe production of sterile injectable formulations. Equipped with automated systems, robust quality control mechanisms, and eco-friendly processes, the facility exemplifies our strategic focus on operational excellence and sustainability.*

*With this new GMP-certified injectable facility, all five of Windlas Biotech Manufacturing plants are complying to this standard and we are well poised to expand our product portfolio offerings in the CDMO space. It will enable us to cater to a wider spectrum of therapeutic areas, thereby contributing to improved patient outcomes and better access to essential medicines.”*

### **About Windlas Biotech Limited**

The company (Windlas) is amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low solubility, the Company excels in developing its own product, process and regulatory intellectual property and provides its customers a comprehensive range of branded products for marketing in the domestic generic pharmaceutical industry. The company also markets a wide variety of its own branded Trade Generics & Institutional products across India. It is a growing exporter of various medical and nutraceutical products.

### **Safe Harbor**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project-related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

**For more information please contact:**



**Windlas Biotech Limited**

CIN: U74899UR2001PLC033407

Ms. Komal Gupta

Email: [Komal@windlasbiotech.com](mailto:Komal@windlasbiotech.com)

Contact no.: +91 124 2821034



**Strategic Growth Advisors Pvt. Ltd.**

CIN: U74140MH2010PTC204285

Mr. Jigar Kavaiya / Parin Narichania

Email: [jigar.kavaiya@sgapl.net](mailto:jigar.kavaiya@sgapl.net) / [parin.n@sgapl.net](mailto:parin.n@sgapl.net)

Contact no.: +91 9920602034 / +91 9930025733